person · Reporting owner

Maris William J

Disclosed activity across 5 companies

Tapewire entity: 86808
SEC CIK: 0001722210

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
DA32 Life Science Tech Acquisition Corp.DALS · Entity 110669	Director · 10% owner · Director by Deputization	August 05, 2021	August 09, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

DA32 Life Science Tech Acquisition Corp.

Report date August 05, 2021 · Filed August 09, 2021

Jointly reported with Section 32 Fund 3, LP, Section 32 GP 3, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common Stock, par value $0.0001 per shareSEC Table II · derivative / convertible security	IndirectThrough DA32 Sponsor LLC	4,695,000	Reported balance After 2021-08-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-05 · Disposition to issuer · Disposed 701,250 · Balance 4,695,000 F1: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F2: On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO. F3: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4: Sponsor is the record holder of the securities reported herein. As a managing member of Sponsor, S32 Fund may be deemed to beneficially own the securities owned directly by Sponsor. As the general partner of S32 Fund, S32 GP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole Managing Member of S32 GP, William J. Maris may be deemed to beneficially own securities owned directly by Sponsor.
Class B Common Stock, par value $0.0001 per shareSEC Table II · derivative / convertible security	Direct	4,665,000	Reported balance After 2021-08-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-08-05 · Disposition to issuer · Disposed 30,000 · Balance 4,665,000 F1: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F5: On August 5, 2021, the Reporting Persons forfeited 30,000 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the IPO disclosing all material information about the Issuer and the IPO. F3: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date.

F2: On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO.

F3: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4: Sponsor is the record holder of the securities reported herein. As a managing member of Sponsor, S32 Fund may be deemed to beneficially own the securities owned directly by Sponsor. As the general partner of S32 Fund, S32 GP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole Managing Member of S32 GP, William J. Maris may be deemed to beneficially own securities owned directly by Sponsor.

F5: On August 5, 2021, the Reporting Persons forfeited 30,000 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the IPO disclosing all material information about the Issuer and the IPO.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cue Health Inc.

Report date September 28, 2021 · Filed September 30, 2021

Jointly reported with Section 32 Fund 2, LP, Section 32 GP 2, LLC

Section 16 reporting ended · disclosed 2021-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,485,535	Reported balance After 2021-09-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-09-28 · Conversion · Acquired 3,485,535 · Balance 3,485,535 F1: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-09-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-09-28 · Conversion · Disposed 3,485,535 · Balance 0 F1: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.

Dave Inc./DE

Report date October 09, 2024 · Filed October 11, 2024

Jointly reported with Section 32 Fund 1, LP, Section 32 GP 1, LLC

Section 16 reporting ended · disclosed 2024-10-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	1,028,232	Reported balance After 2024-10-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-10-09 · Sale · Disposed 1,000,000 · Balance 1,028,232 F1: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim the existence of a "group" and beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim the existence of a "group" and beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein.

Fulcrum Therapeutics, Inc.

Report date July 22, 2019 · Filed July 22, 2019

Jointly reported with Section 32 Fund 2, LP, Section 32 GP 2, LLC

Section 16 reporting ended · disclosed 2019-07-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	464,285	Reported balance After 2019-07-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-07-22 · Conversion · Acquired 464,285 · Balance 464,285 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-07-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-07-22 · Conversion · Disposed 3,250,000 · Balance 0 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

X4 Pharmaceuticals, Inc

Report date November 20, 2017 · Filed November 20, 2017

Jointly reported with Section 32 Fund 1, LP, Section 32 GP 1, LLC

Section 16 reporting ended · disclosed 2017-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	451,362	Reported balance After 2017-11-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-11-20 · Conversion · Acquired 451,362 · Balance 451,362 F1: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-11-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-11-20 · Conversion · Disposed 1,540,500 · Balance 0 F1: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F2: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 09, 2024 Filed Oct 11, 2024 18:00 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	1,000,000	$40.60	$40,600,000.00	Disclosure SEC source: 0001104659-24-108131 · tm2426084-1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,028,232 F1 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim the existence of a "group" and beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
May 10, 2024 Filed May 14, 2024 17:30 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	110,000	$48.90	$5,379,000.00	Disclosure SEC source: 0001104659-24-061249 · tm2414467-1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,028,232 F1 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim the existence of a "group" and beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
May 07, 2024 Filed May 9, 2024 16:01 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	450,000	$48.90	$22,005,000.00	Disclosure SEC source: 0001104659-24-059309 · tm2414012-1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,138,232 F1 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim the existence of a "group" and beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
August 08, 2023 Filed Aug 10, 2023 16:30 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	297,771	$5.73	$1,707,657.13	Disclosure SEC source: 0001104659-23-089830 · tm2323383-1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,588,232 F1 · balance_after: On January 5, 2023, the Issuer effected a 1-for-32 reverse stock split of its Class A Common Stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, every 32 shares of Class A Common Stock issued or outstanding were automatically reclassified into one validly issued, fully-paid and nonassessable new share of Class A Common Stock, with no fractional shares issued. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim the existence of a "group" and beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 30, 2022 Filed Oct 4, 2022 21:29 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	97,300	$0.36	$35,329.63	Disclosure SEC source: 0001104659-22-106047 · tm2227537d1_4.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,352,107 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3261 to $0.4439. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 29, 2022 Filed Sep 29, 2022 20:25 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	400,974	$0.35	$140,781.97	Disclosure SEC source: 0001104659-22-104250 · tm2227076d1_4.xml · nonDerivative · entry 3 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,449,407 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3261 to $0.41. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 28, 2022 Filed Sep 29, 2022 20:25 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	248,782	$0.42	$103,344.04	Disclosure SEC source: 0001104659-22-104250 · tm2227076d1_4.xml · nonDerivative · entry 2 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,850,381 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4 to $0.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:25 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	98,364	$0.44	$42,886.70	Disclosure SEC source: 0001104659-22-104250 · tm2227076d1_4.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,099,163 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4281 to $0.4439. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 15, 2022 Filed Sep 19, 2022 20:52 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	24,181	$0.50	$12,095.34	Disclosure SEC source: 0001104659-22-101278 · tm2226240-1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,197,527 F1 · balance_after: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5 to $0.5024. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 13, 2022 Filed Sep 14, 2022 21:02 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	18,181	$0.51	$9,199.59	Disclosure SEC source: 0001104659-22-100144 · tm2225926d1_4seq1.xml · nonDerivative · entry 2 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,221,708 F1 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 12, 2022 Filed Sep 14, 2022 21:02 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	65,133	$0.53	$34,650.76	Disclosure SEC source: 0001104659-22-100144 · tm2225926d1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,239,889 F1 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
August 15, 2022 Filed Aug 16, 2022 20:00 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	2,094,168	$0.61	$1,266,971.64	Disclosure SEC source: 0001104659-22-091890 · tm2223613d1_4seq1.xml · nonDerivative · entry 2 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,305,022 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.6723. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
August 12, 2022 Filed Aug 16, 2022 20:00 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	656,654	$0.66	$430,765.02	Disclosure SEC source: 0001104659-22-091890 · tm2223613d1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,399,190 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6303 to $0.685. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
August 10, 2022 Filed Aug 10, 2022 20:50 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	361,633	$0.74	$267,608.42	Disclosure SEC source: 0001104659-22-088887 · tm2223149-1_4seq1.xml · nonDerivative · entry 3 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,055,844 F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
August 09, 2022 Filed Aug 10, 2022 20:50 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	1,380,045	$0.76	$1,050,214.25	Disclosure SEC source: 0001104659-22-088887 · tm2223149-1_4seq1.xml · nonDerivative · entry 2 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,417,477 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.74 to $0.7889. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
August 08, 2022 Filed Aug 10, 2022 20:50 UTC	Dave Inc./DE DAVE · Entity 4017	SaleClass A Common Stock	317,404	$0.77	$243,671.05	Disclosure SEC source: 0001104659-22-088887 · tm2223149-1_4seq1.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,797,522 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.74 to $0.819. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
January 05, 2022 Filed Jan 7, 2022 20:42 UTC	Dave Inc./DE DAVE · Entity 4017	GrantClass A Common Stock	98,114,926	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-002609 · doc4.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,114,926 F1 · price: On January 5, 2022, pursuant to that certain Agreement and Plan of Merger, dated as of June 7, 2021 (the "Merger Agreement"), by and among VPC Impact Acquisition Holdings III, Inc. (the "Issuer"), Dave Inc., a Delaware corporation ("Legacy Dave"), and the other parties thereto, the Issuer completed its initial business combination (the "Business Combination"). As a result of the Business Combination, the Issuer changed its name to Dave Inc. In connection with the Business Combination and in accordance with the Merger Agreement, (i) 70,921,980 shares of Series A Preferred Stock and (ii) 1,520,305 shares of Series B-2 Preferred Stock of Legacy Dave held by the Reporting Person were converted into 98,114,926 shares of Class A Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
September 28, 2021 Filed Sep 30, 2021 20:44 UTC	Cue Health Inc. HLTH · Entity 87957	ConversionSeries B Preferred Stock · Derivative	3,485,535	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-21-033115 · form4.xml · derivative · entry 2 Section 32 Fund 2, LP · CIK 0001725306 · 10% owner Section 32 GP 2, LLC · CIK 0001725307 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,485,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · price: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein. Read SEC document
September 28, 2021 Filed Sep 30, 2021 20:44 UTC	Cue Health Inc. HLTH · Entity 87957	ConversionCommon Stock	3,485,535	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-21-033115 · form4.xml · nonDerivative · entry 1 Section 32 Fund 2, LP · CIK 0001725306 · 10% owner Section 32 GP 2, LLC · CIK 0001725307 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,485,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 28, 2021, the Series B Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein. Read SEC document
August 05, 2021 Filed Aug 9, 2021 21:54 UTC	DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669	Disposition to issuerClass B Common Stock, par value $0.0001 per share · Derivative	30,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-032284 · doc4.xml · derivative · entry 2 Section 32 Fund 3, LP · CIK 0001808115 · Director · 10% owner · Director by Deputization Section 32 GP 3, LLC · CIK 0001808116 · Director · 10% owner · Director by Deputization Maris William J · CIK 0001722210 · Director · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665,000 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F5 · kind: On August 5, 2021, the Reporting Persons forfeited 30,000 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the IPO disclosing all material information about the Issuer and the IPO. F5 · shares: On August 5, 2021, the Reporting Persons forfeited 30,000 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the IPO disclosing all material information about the Issuer and the IPO. F1 · derivative.exercise_date: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F1 · derivative.expiration_date: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F3 · ownership.direct: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Read SEC document
August 05, 2021 Filed Aug 9, 2021 21:54 UTC	DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669	Disposition to issuerClass B Common Stock, par value $0.0001 per share · Derivative	701,250	$0.00	$0.00	Disclosure SEC source: 0000899243-21-032284 · doc4.xml · derivative · entry 1 Section 32 Fund 3, LP · CIK 0001808115 · Director · 10% owner · Director by Deputization Section 32 GP 3, LLC · CIK 0001808116 · Director · 10% owner · Director by Deputization Maris William J · CIK 0001722210 · Director · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Through DA32 Sponsor LLC Disclosed balance after: 4,695,000 Underlying: Class A Common Stock · 701,250 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F2 · kind: On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO. F2 · shares: On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO. F1 · derivative.exercise_date: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F1 · derivative.expiration_date: The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date. F3 · ownership.nature: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.nature: Sponsor is the record holder of the securities reported herein. As a managing member of Sponsor, S32 Fund may be deemed to beneficially own the securities owned directly by Sponsor. As the general partner of S32 Fund, S32 GP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole Managing Member of S32 GP, William J. Maris may be deemed to beneficially own securities owned directly by Sponsor. Read SEC document
July 30, 2021 Filed Aug 3, 2021 21:47 UTC	DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669	GrantClass A Common Stock	650,000	$10.00	$6,500,000.00	Disclosure SEC source: 0000899243-21-031450 · doc4.xml · nonDerivative · entry 2 Section 32 Fund 3, LP · CIK 0001808115 · Director · 10% owner · Director by Deputization Section 32 GP 3, LLC · CIK 0001808116 · Director · 10% owner · Director by Deputization Maris William J · CIK 0001722210 · Director · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Through DA32 Sponsor LLC Disclosed balance after: 1,450,000 F3 · kind: DA32 Sponsor LLC ("Sponsor") purchased 650,000 private placement shares of the Issuer directly from the Issuer for $10.00 per share, concurrently with the Issuer's initial public offering. This purchase was exempted pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.nature: Sponsor is the record holder of the securities reported herein. As a managing member of Sponsor, S32 Fund may be deemed to beneficially own the securities owned directly by Sponsor. As the general partner of S32 Fund, S32 GP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole Managing Member of S32 GP, William J. Maris may be deemed to beneficially own securities owned directly by Sponsor. Read SEC document
July 30, 2021 Filed Aug 3, 2021 21:47 UTC	DA32 Life Science Tech Acquisition Corp. DALS · Entity 110669	PurchaseClass A Common Stock	800,000	$10.00	$8,000,000.00	Disclosure SEC source: 0000899243-21-031450 · doc4.xml · nonDerivative · entry 1 Section 32 Fund 3, LP · CIK 0001808115 · Director · 10% owner · Director by Deputization Section 32 GP 3, LLC · CIK 0001808116 · Director · 10% owner · Director by Deputization Maris William J · CIK 0001722210 · Director · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 F1 · kind: Section 32 Fund 3, LP purchased 800,000 shares of the Issuer's Class A common stock for $10.00 per share in the Issuer's initial public offering. F2 · ownership.direct: This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Read SEC document
July 22, 2019 Filed Jul 22, 2019 20:30 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	ConversionSeries B Preferred Stock · Derivative	3,250,000	$0.00	$0.00	Disclosure SEC source: 0001104659-19-041303 · a4.xml · derivative · entry 2 Section 32 Fund 2, LP · CIK 0001725306 · 10% owner Section 32 GP 2, LLC · CIK 0001725307 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 464,285 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein. Read SEC document
July 22, 2019 Filed Jul 22, 2019 20:30 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	ConversionCommon Stock	464,285	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-19-041303 · a4.xml · nonDerivative · entry 1 Section 32 Fund 2, LP · CIK 0001725306 · 10% owner Section 32 GP 2, LLC · CIK 0001725307 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:38 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries D Convertible Preferred Stock · Derivative	1,540,500	$0.00	$0.00	Disclosure SEC source: 0000899243-17-027011 · doc4.xml · derivative · entry 2 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 451,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:38 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	451,362	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-027011 · doc4.xml · nonDerivative · entry 1 Section 32 Fund 1, LP · CIK 0001691436 · 10% owner Section 32 GP 1, LLC · CIK 0001691437 · 10% owner Maris William J · CIK 0001722210 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.